hyperlipoprotein(a) Hyperlipoprotein(a) Lipid apheresis lipoprotein(a)
Conditions
Interventions
Lipid apheresis will be done at day 0, 14, 28 and patients will be further follow up for a total of 42 days. Technique used will be double filtration plasmapheresis using Plasauto-Sigma machine (Asahi
Experimental Device
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult (aged > 18-70 years old) patients with 1. Lp(a) more than 200 nmol/L or 2. Lp(a) more than 125 nmol/L (estimated around 60 mg/dL) and having ASCVD or having high risk for atherosclerosis cardiovascular disease (defined as Thai CV risk more than or equals to 20%)
Exclusion criteria
Exclusion criteria: 1. Having contraindication of heparin use such as hypersensitivity to heparin, history of heparin induced thrombocytopenia, active or uncontrolled bleeding, platelet count < 100,000/mm3 , coagulopathy 2. Recent ASCVD or major surgery within 3 months 3. Receiving PCSK9 inhibitor 4. Having terminal illness 5. Cannot provide consent by themselves 6. History of allergy or reactions to the dialyzers 7. Hypocalcemia (serum total calcium, corrected with albumin < 8.5 mg/dL) on the morning of scheduled LA 8. Hypokalemia (serum potassium < 3.0 mmol/L) on the morning of scheduled LA 9. Hypomagnesemia (serum magnesium < 1.6 mg/dL) on the morning of scheduled LA 10. Severe anemia (Hct <25%)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy Day 0, 3, 7, 14, 28, 42 serum Lp(a) level, total cholesterol, HDL-cholesterol, direct LDL-cholesterol, triglyceride, hsCRP | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety day 0, 14, 28 Adverse events (vascular access AE, DFPP related AE), serum calcium, PT/APTT, fibrinogen | — |
Countries
Thailand
Contacts
Public ContactNuntakorn Thongtang
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed